| abstract |
This disclosure provides methods for the treatment of sporadic inclusion body myositis by novel therapies using therapeutically effective amounts of myostatin antagonists, such as myostatin binding molecules, such as myostatin antibodies or ActRII receptor binding molecules, ActRII receptor antibodies, such as the Bimargum mon antibody And other muscle sparing disorders. |